BRAIN and NERVE－神経研究の進歩74巻5号

2022年05月発行

増大特集 次の一手—神経筋疾患難治例をどのように治療するか

脳主幹動脈の動脈硬化がびまん性かつ高度で，複数の抗血小板薬投与によっても再発を繰り返す脳梗塞—抗血小板薬投与中に再発した脳梗塞症例

著者： 出口一郎¹

所属機関： ¹埼玉医科大学国際医療センター脳卒中内科

ページ範囲：P.621 - P.628

文献概要

実臨床において，治療指針どおりに治療を行っても再発を認めるあるいは繰り返す症例を少なからず経験する。動脈硬化が主体の非心原性脳梗塞の再発予防では，抗血小板療法が主体となる。抗血小板薬さえ服薬あるいは処方していれば安心と思う患者や医療従事者が少なくない。無論，抗血小板薬は再発予防に欠かせない薬である。しかしながら，抗血小板療法だけでは再発予防としては不十分であり，危険因子の管理も合わせて行うことで，その予防効果を最大限引き出すことが可能となる。

参考文献

1）日本脳卒中学会脳卒中ガイドライン委員会（編）: 脳卒中治療ガイドライン2021. 協和企画, 東京, 2021

2）Weimar C, Diener HC, Alberts MJ, Steg PG, Bhatt DL, et al: The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the REduction of Atherothrombosis for Continued Health (REACH) registry. Stroke 40: 350-354, 2009

3）Diener HC: Modified-release dipyridamole combined with aspirin for secondary stroke prevention. Aging Health 1: 19-26, 2005

4）西川政勝, 駒田文彦: アスピリン・クロピトグレルレジスタンス克服への試み. 血栓と循環18: 54-63, 2010

5）Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR: Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336: 195-198, 2008

6）Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV: Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 167: 1593-1599, 2007

7）Snoep JD, Hovens MMC, Eikenboom JC, van der Bom JG, Jukema JW, et al: Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 154: 221-231, 2007

8）Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, et al: Clopidogrel non-responsiveness and risk of cardiovascular morbidity: an updated meta-analysis. Thromb Haemost 103: 841-848, 2010

9）Wang Y, Wang Y, Zhao X, Liu L, Wang D, et al: Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 369: 11-19, 2013

10）Johnston SC, Easton JD, Farrant M, Barsan W, Coneit RA, et al: Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 379: 215-225, 2018

11）Rahman H, Khan SU, Nasir F, Hammad T, Meyer MA, et al: Optimal duration of aspirin plus clopidogrel after ischemic stroke or transient ischemic attack. Stroke 50: 947-953, 2019

12）Toyoda K, Uchiyama S, Yamaguchi T, Easton JD, Kimura K, et al: Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol 18: 539-548, 2019

13）藤本一眞, 藤城光弘, 加藤元嗣, 樋口和秀, 岩切龍一, 他: 抗血栓薬服用者に対する消化器内視鏡診療ガイドライン. 日本消化器内視鏡学会雑誌54: 2075-2102, 2012

14）Valgimigli M, Bueno H, Byrne RB, Collet JP, Costa F, et al: 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39: 213-260, 2018

15）Demcsák A, Lantos T, Bálint ER, Hartmann P, Vincze Á, et al: PPIs are not responsible for elevating cardiovascular risk in patients on clopidogrel-a systematic review and meta-analysis. Front Physiol 9: 1550, 2018［doi: 10.3389/fphys.2018.01550］

16）Katsanos AH, Filippatou A, Manios E, Deftereos S, Parissis J, et al: Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials. Hypertension 69: 171-179, 2017

17）日本高血圧学会高血圧治療ガイドライン作成委員会（編）: 高血圧治療ガイドライン2019. ライフサイエンス出版, 東京, 2021

18）長尾毅彦: 抗凝固療法中や抗血小板療法中の頭蓋内出血—アジア人の特徴も踏まえて. Cardio-Coagulation 4: 161-166, 2017

19）Qiu J, Ye H, Wang J, Yan J, Wang J, et al: Antiplatelet therapy, cerebral microbleeds, and intracerebral hemorrhage: a meta-analysis. Stroke 49: 1751-1754, 2018

20）Wilson D, Charidimou A, Ambler G, Fox ZV, Gregoire S, et al: Recurrent stroke risk and cerebral microbleed burden in ischemic stroke and TIA: a meta-analysis. Neurology 87: 1501-1510, 2016

21）Miyatani F, Kuriyama N, Watanabe I, Nomura R, Nakano K, et al: Relationship between Cnm-positive Streptococcus mutans and cerebral micro bleeds in humans. Oral Dis 21: 886-893, 2015

22）Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, et al: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355: 549-559, 2006

23）Tramacere I, Boncoraglio GB, Banzi R, Del Giovane C, Kwag KH, et al: Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. BMC Med 17: 67, 2019［doi: 10.1186/s12916-019-1298-5］

24）Hosomi N, Nagai Y, Kohriyama T, Ohtsuki T, Aoki S, et al: The Japan statin treatment against recurrent stroke (J-STARS): a multicenter, randomized, open-label, parallel-group study. EBioMedicine 2: 1071-1078, 2015

25）Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, et al: A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med 382: 9, 2020［doi: 10.1056/NEJMoa1910355］

26）Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, et al: Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke 39: 2052-2058, 2008

27）Watson PD, Joy PS, Nkonde C, Hessen SE, Karalis DG: Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel--versus--aspirin + clopidogrel in patients with cardiovascular disease. Am J Cardiol 104: 1052-1054, 2009

28）Shinohara Y, Gotoh F, Tohgi H, Hirai S, Terashi A, et al: Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients: subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis 26: 63-70, 2008